Why I’m Choosing Not to Take GLP-1s, Even Though Everyone Expects Me To
I’m a candidate for the meds, but they’re not for me—at least for now.
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
Novo, Regeneron and Pfizer all landed weight loss deals with China-based companies last year.
Hormone therapy combined with tirzepatide linked to greater weight loss after menopause
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause.
GLP-1 medications: A comprehensive overview
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
Food Companies Are Targeting Users of Weight-Loss Drugs With ‘GLP-1 Friendly’ Labels
(MedPage Today) — Meals and snacks with “GLP-1 Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) to lose weight…
Summary of JP Morgan Conference in Obesity and Metabolic Diseases
Here’s a summary of the major announcements and trends from the 44th Annual JP Morgan Healthcare Conference in San Francisco (January 12–15, 2026) specifically in the areas of obesity, weight-loss drugs, metabolic disease, and adjacent therapies: (BioSpace) Fierce Biotechscanx.tradeReutersReutersAd Hoc News 🧠 1. Shift Toward Oral Obesity DrugsA major theme at JPM 2026 was the […]
Day 1 @ JP Morgan in Obesity Drugs and Therapies
JP Morgan 2026: Obesity & GLP-1 Therapies Take Center StageWhat the Latest Deals and Data Mean for the Future of Metabolic MedicineThe J.P. Morgan Healthcare Conference once again served as the bellwether for where biotech and pharma are headed—and in 2026, GLP-1 and obesity therapeutics dominated the conversation.From next-generation incretin drugs to RNA-based obesity targets […]
Day 2 @ JP Morgan in Obesity Drugs and Therapies
Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments Fierce PharmaPharmaceutical TechnologyReutersFierce BiotechPharmaceutical Technology 🧪 New & Emerging TherapiesAmgen’s MariTide weight-loss programAmgen touted positive data on its experimental obesity drug MariTide, showing the therapy helped trial participants maintain significant […]
Cardiologist explains benefits of GLP-1 drugs go beyond just weight loss: ‘Future of how we treat heart, liver…’
Everyone’s talking about weight loss drugs like Ozempic, Wegovy and Mounjaro and their implications on weight loss – but their benefits go way beyond that.
JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)
JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)1. Shift From “Weight Loss” to Chronic Metabolic DiseaseDay 3 discussions made it clear that industry messaging is moving away from cosmetic weight loss and toward lifelong metabolic disease management.Key framing heard repeatedly:Obesity as a multisystem, chronic diseaseGLP-1–based therapies positioned alongside statins or antihypertensives, […]